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Malignant pleural mesothelioma (MPM) is an aggressive malignancy that occurs extremely rarely in the
pediatric population. It carries a dismal prognosis. Adult studies are often used to guide therapy in the
pediatric population, as a limited number of case reports form the body of pediatric literature. Herein, we
document the course and treatment of an 8-year old male diagnosed with MPM. The diagnosis
came after he presented to his family physician with dyspnea and was found to have a large right-sided
chest mass on subsequent imaging. Through an initial right pneumonectomy and subsequent chest wall
excision, followed by chemotherapy with Pemetrexed and Cisplatin he remains virtually disease free
today, almost 2 years following surgery.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Paragraph setting the train of thought
Malignant pleural mesothelioma (MPM) is an aggressive ma-
lignancy that occurs extremely rarely in the pediatric population
and carries a dismal prognosis [1]. Less than 5% of presenting cases
are in children, and less than 300 cases of such have been published
in the literature [1,2]. MPM in children appears to represent a
different entity from its adult counterpart, as it is not associated
with asbestos or radiation exposure [1,3], and much of the infor-
mation regarding the disease is derived from the limited number of
case reports available. There is no accepted standard of treatment
for childhood MPM, and much of our current therapy is guided by
the data available from adult studies. We report a case of an 8-year
old male diagnosed with MPM who was successfully treated with
pneumonectomy, chest wall excision, and subsequent chemo-
therapy using Pemetrexed and Cisplatinwith hopes of adding to the
pediatric body of literature and improving the outcomes for pedi-
atric patients with MPM.
2. Case report
An eight year old male who originally presented to his family
physician complaining of dyspnea, weight loss and lethargy wastment of Surgery, 2D, Walter
, Edmonton, Alberta T6G 2B7,
.
Inc. This is an open access article ureferred to the department of Pediatric Surgery at the University of
Alberta/Stollery Children’s Hospital. There was no known
exposure to asbestos or radiation. A chest radiograph and CT scan
(Figs. 1 and 2 respectively) demonstrated a large right-sided chest
mass that appeared to be originating from the right upper lobe and
encroaching on the right middle lobe. The dimensions of the mass
measured roughly 10.6  7.5  7.7 cm.
Needle biopsy was initially preformed on the mass, and sug-
gested the possibility of malignant cells; however, it was non-
diagnostic. The differential remained broad, including infectious
(including fungal, as the child had recently traveled to Arizona) and
inﬂammatory etiologies in addition to neoplastic possibilities.
With the aim of ascertaining a diagnosis, the child was taken to
the operating room for a thoracotomy and open lung biopsy. A few
expert opinions from cancer centers indicated that frozen section
pathology was consistent with an undifferentiated or poorly
differentiated carcinoma, such as a choriocarcinoma. The pathology
was then reviewed by Dr. Chris Fletcher, chief of onco-pathology at
the Dana-Farber/Harvard Cancer Center and a ﬁnal diagnosis of
malignant mesotheliomadepithelioid tye was reached. Dr. Fletcher
specializes in onco-pathology including mesothelioma. Patholog-
ical ﬁndings of note included electronmicroscopy of the tumor cells
that showed numerous long, narrow microvilli, and hematoxylin-
eosin staining of the tumor that showed cords of tumor cells and
epithelioid nuclei with large pink eosinophilic cytoplasm (Fig. 3).
Immunohistochemical staining of the tumor with an antibody
against epithelial membrane antigen was also positive (Fig. 4).
Immunohistochemistry also demonstrated multifocal convincingnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest radiograph with right-sided chest mass.
Fig. 3. Hematoxylin-eosin staining of the tumor showing cords of tumor cells and
epithelioid nuclei and large pink eosinophilic cytoplasm (400 original magniﬁcation).
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sothelioma. Synovial sarcomawas not ruled out by genetic analysis,
as upon expert review in Boston, the diagnosis of synovial sarcoma
was not further considered following the immunohistochemistry
results. All of these results supported the diagnosis of malignant
mesotheliomadepithelioid type.
Bone and PET scanning failed to demonstrate any evidence of
metastatic disease, and the lesion appeared to be well circum-
scribed and localized to the right lung (Fig. 5). As such the child
was taken to the operating room for a right thoracotomy andFig. 2. CT scan showing axonal view of right chest mass.pneumonectomy. Intraoperatively, the tumor did not have the
characteristic appearance of a malignant mesothelioma, and there
was no evidence of a pleural rind encasing the lung or invading the
chest wall. Instead, the tumor appeared to be well localized within
the visceral pleura and extending into the lung parenchyma
(Fig. 6a and b). The tumor did not appear to be of hilar origin, and
this would be unusual if it were the case. Most commonly the tumor
is found in the pleural lining surrounding the periphery of the lung.
We believe that the tumor could have possibly originated in the
visceral pleura of the horizontal or oblique ﬁssure, and had grown
to involve all three lobes of the right lung. A decision was made to
perform a right pneumonectomy, as there was no evidence of in-
vasion or spread to the chest wall, diaphragm or pericardium in the
setting of a tri lobar tumor.
Post-operatively, the child didwell, but unfortunately developed
a small metastatic lesion in the thigh that was excised. Additionally,
the child was found to have recurrent disease involving the right
chest wall on PET scanning roughly two months following pneu-
monectomy. As a result, he was again taken to the operating room
for excision of the right chest wall and removal of ribs four through
eight. The pathologic margins were clear, and Prolene mesh was
used to replace the chest wall.
The child received chemotherapy post-operatively and has had a
very good response. He received eight courses of chemotherapy for
a total duration of one year of therapy. Six courses of PemetrexedFig. 4. Immunohistochemical staining of the tumor with an antibody against epithelial
membrane antigen (100 original magniﬁcation).
Fig. 5. PET scan demonstrating disease localized within the right lung.
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given, with cycle intervals of every three weeks. The child was
switched to Pemetrexed and Carboplatin for two additional courses
to complete one year of chemotherapy, as the use of Cisplatin led to
ototoxicity that necessitated the switch. There has been no further
surgical intervention required. He is currently doing extremely well
and is roughly 30 months following pneumonectomy and 23
months following chest wall excision. At present the disease status
of the child is: no evidence of disease (NED).
3. Discussion
Pediatric MPM is an extremely rare disease. To the best of our
knowledge, there are less than 300 published cases [1]. The disease
appears to be a different entity than its adult counterpart, as it is not
associated with asbestos or radiation exposure [1,3]. A case of pe-
diatric MPM has been reported after in utero Isoniazid exposure [4]
as well as in a child with AtaxiaeTelangiectasia [5] e a hereditary
disorder characterized in part by a susceptibility to malignancy.
However, our patient did not have any of the above conditions, and
the exact pathophysiology of the disease remains relatively un-
known. As such, there is currently no accepted standard of treat-
ment, and the adult data often guides our decision making. This
seems to be less than ideal, again as childhoodMPM appears to be aFig. 6. a) Large right-sided tumor, primarily in the right upper lobe and inﬁltradifferent entity, which could theoretically respond differently and
require alternate treatment strategies than the adult form.
Considerable debate exists in regards to appropriate therapy in
the adult population. Some studies suggest shorter survival times
and increased morbidity in patients treated with extra-pleural
pneumonectomy (EPP) combined with chemo and radiotherapy for
MPM [6]. On the other hand, others have claimed that EPP is the
only intervention that has been shown to result in long-term, dis-
ease-free survival in select patients with favorable prognostic
indices [7]. The current thought is that surgery with either pleur-
ectomy or [EPP] combined with multimodal therapy (chemo-
therapy and radiation) is considered the best treatment option for
select patients. Without treatment the expected survival is, unfor-
tunately, 6e8 months [8].
EPP has been described as an option for curative intent of
localized MPM in children [9] and newer chemotherapy regimes
with the combination of Pemetrexed and Cisplatin have yielded
higher response rates, which could improve survival when used in
combination with surgical resection [10]. However, alternative
chemotherapy regimes have been proposed for the treatment of
childhoodMPM and one case has been reported of an 8-year old girl
diagnosed with sarcomatoid pleural malignant mesothelioma, who
had complete tumor response after decortication and treatment
with Ifosfamide, Carboplatin, Etoposide, Vincristine, Adriamycin,
and Cyclophosphamide (ICE-VAC) [11].
However, we are still left with the fact that treatment of child-
hood MPM remains a challengedas does the diagnosis of MPM
itself. In a study by Fraire et al., 14 tissue specimens previously
identiﬁed as MPM were examined by a panel of pathologists, and
only eight were subsequently accepted as MPM. Multiple centers
were involved in reviewing our biopsy sample, and an intense re-
view was undertaken before the diagnosis was made. The choice to
perform a right-sided pneumonectomy (as opposed to an EPP) was
made on the basis that the disease appeared to be localized within
the right lung and did not involve the diaphragm, chest wall or
pericardium. An EPP seemed overly radical, and considering the
associated morbidity of the procedure, was not performed. How-
ever, with this approach, further surgery in the form of removal of
the chest wall was required as PET scanning did demonstrate
postoperative chest wall disease. The choice of chemotherapy with
Pemetrexed and Cisplatin was based on the adult protocols for
MPM at our institution, and given the clinical and radiological
responsewith the aforementioned, radiotherapy has not been used.
In turn, we have described what we feel has been a successful
treatment strategy for childhood MPM.
Further documented cases of successful treatment strategies
are required in order to strive for an acceptable standard of care.ting the right middle and inferior lobe. b) Tumor and right lung removed.
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Childhood MPM is an extremely rare tumor in the pediatric
population that caries a dismal prognosis. Although additional
work is needed to develop a standard of care for the disease; we
have documented successful treatment of childhood MPM with a
pneumonectomy followed by chest wall excision, and chemo-
therapy with Pemetrexed and Cisplatin.
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